1 January 2020 in OncoImmunology
Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved following a clinical trial that showed response rates in at least 43% of patients. While this approval marks a major advance in the treatment of TNBC it may be possible to improve the efficacy of ICI therapies through further modulation of the suppressive tumor immune microenvironment (TIME). Several factors may limit immune response in TNBC including aberrant growth factor signaling, such as VEGFR2 and cMet signaling, inefficient vascularization, poor delivery of drugs and immune cells, and the skewing of immune cell populations toward immunosuppressive phenotypes. Here we investigate the immune-modulating properties of AXT201, a novel 20 amino-acid integrin-binding peptide in two syngeneic mouse TNBC models: 4T1-BALB/c and NT4-FVB. AXT201 treatment improved survival in the NT4 model by 20% and inhibited the growth of 4T1 tumors by 47% over 22 days post-inoculation. Subsequent immunohistochemical analyses of 4T1 tumors also showed a 53% reduction in vascular density and a 184% increase in pericyte coverage following peptide treatment. Flow cytometry analyses demonstrated evidence of a more favorable anti-tumor immune microenvironment following treatment with AXT201, including significant decreases in the populations of T regulatory cells, monocytic myeloid-derived suppressor cells, and PD-L1 expressing cells and increased expression of T cell functional markers. Together, these findings demonstrate immune-activating properties of AXT201 that could be developed in combination with other immunomodulatory agents in the treatment of TNBC.
22 August 2025 in bioRxiv
Oncolytic peptides are amphipathic peptides that specifically induce cell death in cancer cells by rupturing the cell membrane. Despite their therapeutic potential, few have advanced to clinical trials, and none have been approved for cancer treatment, highlighting the need for more potent and safe candidates. Moreover, the structure-activity relationship (SAR) of oncolytic peptides remains poorly understood. To address these challenges, we designed a series of peptides based on the previously reported oncolytic peptide CKS1 and evaluated their activity to induce cancer cell death. By comparing the structures and the activities of these peptides, we discovered novel insights in the SAR of oncolytic peptides. Among the peptides, we identified NF27 as the most potent peptide. NF27 showed broad cytotoxicity across multiple cancer types but displayed minimal toxicity against healthy cells and low hemolysis. Cell death induced by NF27 was immunogenic and promoted infiltration of immune cells in murine tumors. In murine tumor models, NF27 effectively suppressed tumor growth and achieved complete eradication in some cases, with no observable side effects. These findings highlight NF27 as a promising lead peptide for the development of safe and effective oncolytic therapies. One Sentence Summary: We identified NF27, a novel oncolytic peptide that induces immunogenic cancer cell death and eradicates tumors with low toxicity via SAR study.
24 September 2026 in medRxiv
Frequent injections remain a substantial burden in the treatment of neovascular age-related macular degeneration (nAMD). AXT107 (gersizangitide) is a long-acting, integrin-disrupting peptide designed for suprachoroidal administration. In the phase 1/2a, open-label DISCOVER trial, 15 participants with active nAMD received a single suprachoroidal injection of AXT107 microparticles at 0.125, 0.25, or 0.5 mg and were followed for 40 weeks. Safety and tolerability were the primary outcomes; visual acuity, retinal thickness, and time to protocol-specified rescue anti-vascular endothelial growth factor treatment were exploratory outcomes. No AXT107-related serious adverse events, clinically significant intraocular inflammation, or sustained intraocular pressure elevations were observed. Fourteen eyes met the protocol-specified baseline imaging criterion for efficacy analyses. Among these eyes, two treatment-experienced eyes completed 40 weeks without protocol-specified rescue, and a third first received protocol-specified rescue at week 36. Anatomical improvements were observed in at least one eye in each dose cohort, although responses varied. A single suprachoroidal injection of AXT107 was well tolerated in this small first-in-human study. The exploratory findings warrant evaluation in a controlled trial One Sentence Summary: Suprachoroidal AXT107 was well tolerated, with some eyes remaining free of protocol-specified rescue for up to 40 weeks.